JP2022532534A5 - - Google Patents
Info
- Publication number
- JP2022532534A5 JP2022532534A5 JP2021565875A JP2021565875A JP2022532534A5 JP 2022532534 A5 JP2022532534 A5 JP 2022532534A5 JP 2021565875 A JP2021565875 A JP 2021565875A JP 2021565875 A JP2021565875 A JP 2021565875A JP 2022532534 A5 JP2022532534 A5 JP 2022532534A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- amino acid
- polypeptide chain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001728A JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1906685.1 | 2019-05-13 | ||
| GBGB1906685.1A GB201906685D0 (en) | 2019-05-13 | 2019-05-13 | Activatable protein constructs and uses thereof |
| GBGB1910254.0A GB201910254D0 (en) | 2019-05-13 | 2019-07-17 | Activatable protein constructs and uses thereof |
| GB1910254.0 | 2019-07-17 | ||
| GBGB1917678.3A GB201917678D0 (en) | 2019-05-13 | 2019-12-04 | Activatable protein constructs and uses thereof |
| GB1917678.3 | 2019-12-04 | ||
| GBGB2001196.1A GB202001196D0 (en) | 2019-05-13 | 2020-01-28 | Activatable protein constructs and uses thereof |
| GB2001196.1 | 2020-01-28 | ||
| PCT/EP2020/063362 WO2020229553A1 (en) | 2019-05-13 | 2020-05-13 | Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001728A Division JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532534A JP2022532534A (ja) | 2022-07-15 |
| JP2022532534A5 true JP2022532534A5 (enExample) | 2023-05-22 |
| JP7617027B2 JP7617027B2 (ja) | 2025-01-17 |
Family
ID=67384589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565875A Active JP7617027B2 (ja) | 2019-05-13 | 2020-05-13 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
| JP2025001728A Pending JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001728A Pending JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192899A1 (enExample) |
| EP (1) | EP3969116A1 (enExample) |
| JP (2) | JP7617027B2 (enExample) |
| KR (1) | KR20220008841A (enExample) |
| CN (2) | CN113840634B (enExample) |
| AU (1) | AU2020276891A1 (enExample) |
| BR (1) | BR112021022661A2 (enExample) |
| CA (1) | CA3138827A1 (enExample) |
| GB (4) | GB201906685D0 (enExample) |
| IL (1) | IL287890A (enExample) |
| MX (1) | MX2021013844A (enExample) |
| SG (1) | SG11202112114YA (enExample) |
| WO (1) | WO2020229553A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2022548310A (ja) * | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス，インコーポレイテッド | 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| US20240002509A1 (en) * | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CA3251615A1 (en) * | 2022-01-31 | 2023-08-03 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses |
| IL315768A (en) * | 2022-03-30 | 2024-11-01 | Centessa Pharmaceuticals Uk Ltd | Bispecific anti-CD3 and anti-PD-L1 activatable proteins and their uses |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| AU2023271317A1 (en) | 2022-05-16 | 2024-11-07 | Byondis B.V. | Novel masked antibodies |
| GB202302074D0 (en) * | 2023-02-14 | 2023-03-29 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2024218512A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof |
| EP4698562A1 (en) * | 2023-04-19 | 2026-02-25 | Centessa Pharmaceuticals (UK) Limited | Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof |
| WO2024241208A1 (ko) * | 2023-05-19 | 2024-11-28 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
| CN121866269A (zh) * | 2023-09-14 | 2026-04-14 | Abl生物公司 | 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法 |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| MX2017003847A (es) * | 2014-09-25 | 2017-12-15 | Amgen Inc | Proteinas biespecificas activables por proteasas. |
| JP7065782B2 (ja) * | 2016-03-18 | 2022-05-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｃｄ２０免疫療法のための組成物および方法 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| SG11201909160WA (en) * | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2019
- 2019-05-13 GB GBGB1906685.1A patent/GB201906685D0/en not_active Ceased
- 2019-07-17 GB GBGB1910254.0A patent/GB201910254D0/en not_active Ceased
- 2019-12-04 GB GBGB1917678.3A patent/GB201917678D0/en not_active Ceased
-
2020
- 2020-01-28 GB GBGB2001196.1A patent/GB202001196D0/en not_active Ceased
- 2020-05-13 MX MX2021013844A patent/MX2021013844A/es unknown
- 2020-05-13 SG SG11202112114YA patent/SG11202112114YA/en unknown
- 2020-05-13 CA CA3138827A patent/CA3138827A1/en active Pending
- 2020-05-13 JP JP2021565875A patent/JP7617027B2/ja active Active
- 2020-05-13 WO PCT/EP2020/063362 patent/WO2020229553A1/en not_active Ceased
- 2020-05-13 CN CN202080034818.9A patent/CN113840634B/zh active Active
- 2020-05-13 BR BR112021022661A patent/BR112021022661A2/pt unknown
- 2020-05-13 KR KR1020217038644A patent/KR20220008841A/ko active Pending
- 2020-05-13 AU AU2020276891A patent/AU2020276891A1/en active Pending
- 2020-05-13 CN CN202510701821.6A patent/CN120554533A/zh active Pending
- 2020-05-13 EP EP20726749.3A patent/EP3969116A1/en active Pending
- 2020-05-13 US US17/610,899 patent/US20230192899A1/en active Pending
-
2021
- 2021-11-07 IL IL287890A patent/IL287890A/en unknown
-
2025
- 2025-01-06 JP JP2025001728A patent/JP2025039660A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532534A5 (enExample) | ||
| US12378323B2 (en) | IgM and IgE heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity | |
| US12344679B2 (en) | CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof | |
| US20220017640A1 (en) | Activatable bispecific antibodies | |
| Kontermann et al. | Bispecific antibodies | |
| JP2021519100A5 (enExample) | ||
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| KR20180012860A (ko) | 이종 이량체 다중 특이적 항체 포맷 | |
| US20220396635A1 (en) | Trivalent binding molecules | |
| EP2729499A2 (en) | Multispecific mutated antibody fab fragments | |
| JP2021516537A5 (enExample) | ||
| JP2025160226A5 (enExample) | ||
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JP2021515544A5 (enExample) | ||
| US20260085113A1 (en) | All-in-one agonistic antibodies | |
| JP2025509272A5 (enExample) | ||
| Xie et al. | A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells | |
| RU2021135215A (ru) | Активируемые белковые конструкции и их применение | |
| JP2025511002A5 (enExample) | ||
| JP2022545368A5 (enExample) | ||
| HK40126819A (zh) | 一体化激动性抗体 | |
| EP4688840A1 (en) | Agonistic split antibodies | |
| WO2025162454A1 (zh) | 双特异性抗体和细胞因子融合蛋白及其应用 | |
| Gerspach | Activatable bispecific antibodies The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor-or inflammation-tissue/disease specific proteases (eg tumor-or inflammation-specific proteases); and the preparation and use of such bispecific antibodies. | |
| RU2019135842A (ru) | Полиспецифические полипептидные конструкции, обладающие ограниченным связыванием с сd3, и способы их применения |